CombiMatrix said that it had record prenatal microarray volume of 1,126 tests in the fourth quarter.
NanoString CEO Brad Gray said on a conference call that oncology was once a primary driver of new instrument placements.
The firm said that it placed 38 XT-8 analyzers in Q4, bringing the total installed base of the instrument to 540 as of the end of 2014.
The firm is also positioning MassArray as a complementary technology to NGS, and hopes to tap into the LDT and liquid biopsy arenas.
The molecular diagnostics firm offered more than 3.2 million shares of its stock at $2.80 per share as part of the offering.
A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.
The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.
In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.
With a new collection, PLOS highlights negative results it has published.